It should be the discretion of individual physicians, not insurance companies or pharmacies, to substitute a branded biologic for a biosimilar, which goes back to putting the physician in the decision making process, not the non clinical analyzers. While the search for "cheap" continues...
Posted to
The Medical Quack .... by Barbara Duck
on 08-14-2008
Filed under: Medically Related, Technology, My Commentaries, DNA, Genomics, Biotech, Research, Congress, Pharmaceuticals, Biosimilars
Warfarin is the second-most-likely drug, to cause adverse events requiring hospitalization. The use of warfarin sensitivity testing in the U.S. could avoid 85,000 serious-bleeding incidents. More in the way of personalized medicine and if you were a patient determined to have an adverse reaction...
While pharmaceutical companies are struggling , Biotech continues to grow at a rapid rate, and is part of the reason for pharma’s big investments in bio tech companies. Innovative and new products continue to flow, although there are some downsides with companies that fail to meet goals and thus...